SINGAPORE, MINNEAPOLIS (October 11, 2017) – In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering personalized medicine and care in medical oncology, gastroenterology, and family medicine.
OneOme’s RightMed® pharmacogenomic (PGx) solution identifies how a patient's DNA and current medications may affect their response to medications. Tucker Medical was an early adopter of the RightMed test, offering it to patients as an innovative care option and to assess the appropriate chemotherapy and supportive care medications for cancer patients. Since late 2016, Tucker Medical has integrated usage of OneOme’s pharmacogenomics solution into its clinical workflow and across all specialties.
“OneOme’s RightMed test arms patients with a lifetime of information that is valuable any time a patient needs a medication, either now or in the future,” Paul Owen, CEO of OneOme, said. “Dr. Tucker is sought out by patients around the world for his comprehensive approach to cancer treatment and prevention. We believe the RightMed test is a strong complement to his other offerings. Patients at Tucker Medical can feel confident knowing they have the latest information about how their unique DNA affects their medication response.”
OneOme’s RightMed test has the potential to reduce adverse drug reactions, lower re-hospitalization rates, and improve health outcomes by analyzing how a person’s genes may predict his or her response to medications. The flourishing Tucker Medical partnership demonstrates OneOme’s goal to integrate its pharmacogenomic testing and clinical support tools into the clinical setting. Tucker Medical adopted RightMed PGx testing to further the prevention, diagnosis, and treatment of chronic disease, and to guide its medication choices for oncology, gastroenterology, and palliative treatments.
“The patients we see in Singapore are a diverse mix of ethnicities and the OneOme solution helps us deliver precision medicine safely. The RightMed test allows our doctors to order, not only an effective medication, but one that we believe is safest for our patient. Routine use of pharmacogenomics in the clinic helps us keep our oath to ‘Do No Harm,’” Dr. Steven Tucker, founder of Tucker Medical, added.
OneOme’s pharmacogenomic testing and clinical support tools are easy-to-use, intuitive, and ready to be integrated into clinical practices. The RightMed comprehensive test covers hundreds of medications for a wide range of medical indications including psychiatric conditions, cancer, chronic pain, cardiovascular disease, and it can be integrated into electronic medical records (EMRs). To date, over 450 locations from over 22 different countries have ordered OneOme’s RightMed test, and OneOme continues to build research and commercial partnerships across the globe.
About Tucker Medical
Tucker Medical Pte Ltd, is a Singapore-based multi-specialty medical practice that provides both general primary care and sub-specialty services. Founded in 2011, Tucker Medical now offers integrated care in oncology, gastroenterology, hepatology, family medicine, nutrition, and mental health services in Singapore and to patients across Southeast Asia. To learn more about Tucker Medical, visit tuckermedical.com.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.
Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.